Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key inclusion criteria:~1. Documented history of migraine in the 12 months prior to screening~2. 4-14 days per month of migraine symptoms~3. \>=80% diary compliance during the Baseline period~Key exclusion criteria:~1. \>50 years old at migraine onset~2. Pregnant or nursing~3. History of cluster or hemiplegic headache~4. Evidence of seizure or major psychiatric disorder~5. Score of 19 or higher on the BDI~6. Active chronic pain syndrome~7. Cardiac or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AMG334 70 mg (Type: EXPERIMENTAL): AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
- AMG334 140 mg (Type: EXPERIMENTAL): AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Two pre-filled syringes containing placebo identical in appearance to erenumab

Based on this trial design, predict the completion outcome and termination type (if applicable).